Atul Deodhar, ACR 2020 – Tofacitinib for Ankylosing Spondylitis
Atul Deodhara (Oregon Health & Science University, Portland, OR, USA) kindly discusses the phase III results of the oral JAK inhibitor, tofacitinib, in the treatment of adult patients with Ankylosing Spondylitis. His abstract entitled: ‘Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study’ (NCT03502616) was presented at the ACR Convergence 2020, 5-9 November 2020.
- What is the rationale for the use of JAK inhibitors in the treatment of ankylosing spondylitis (AS)? (0:16)
- Could you tell me a little about the aims, design and eligibility criteria for the Phase III clinical study you presented investigating tofacitinib in the treatment of AS? (1:40)
- What were the major efficacy findings from the primary analysis of this study? (2:56)
- What were the major safety findings? (3:58)
- What do you think will be the next steps in the clinical development of tofacitinib, and other JAK inhibitors, in the treatment of ankylosing spondylitis? (4:57)
Disclosures: Atul Deodhar has acted as a consultant/participated in advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Glaxo Smith & Kline, Janssen, Novartis, Pfizer and UCB. He has also received research grants from AbbVie, Eli Lilly, Glaxo Smith & Kline, Novartis, Pfizer and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Axial Spondyloarthritis
Xenofon Baraliakos, ACR 2022: Bimekizumab in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis – 52 week findings from BE MOBILE 1 and 2
Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits both IL-17F and IL‑17A, was recently investigated in the phase 3 BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743) clinical trials for active non-radiographic axial spondyloarthritis and ankylosing spondylitis, respectively. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany) to discuss […]
Sofia Ramiro, ACR 2022: Ixekizumab for radiographic axial spondyloarthritis – findings from the COAST-V trial
The COAST-V trial (NCT02696785) investigated the efficacy and safety of ixekizumab in patients with radiographic axial spondyloarthritis who were biological disease-modifying anti-rheumatic drug naïve. It was a pleasure to talk with Dr. Sofia Ramiro (Leiden University Medical Center, Leiden, Netherlands) to discuss the findings in terms of patient reported outcomes at weeks 16 and 52 […]
Xenofon Baraliakos, EULAR 2022: Bimekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis – BE MOBILE 1
BE MOBILE 1 (ClinicalTrials.gov Identifier: NCT03928704) is a a phase 3 study investigating bimekizumab in the treatment of active non-radiographic axial spondyloarthritis. touchIMMUNOLOGY were delighted to speak with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) around the aims of the BE MOBILE 1 study and the safety and efficacy findings. The abstract ‘Bimekizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!